Skip to search formSkip to main contentSkip to account menu

metastatic renal carcinoma

Known as: carcinoma metastatic renal, renal carcinoma metastatic 
National Institutes of Health

Related topics

Related topics

1 relation
renal metastasis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center.
e16112 Background: Treatment of poor risk metastatic renal carcinoma (mRCC) is challenging, and empiric combinations may be… 
2015
2015
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (IMRCC), in patients (pt) treated with pazopanib (Pz) as first line for metastatic renal carcinoma…
e15597 Background: The IMRCC prognostic model for mRCC treated with VEGF-targeted agents (Heng, JCO '09) has been externally… 
2015
2015
2602 Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (IMRCC). The SPAZO…
2014
2014
PDGFBR expression on perivascular cells influence the prognosis for TKI-treated mRCC pateints in a retrospective cohort study.
e15599 Background: Tyrosine kinase inhibitors (TKIs) have improved the outcome for patients with metastatic renal carcinoma (mRCC… 
Review
2013
Review
2013
Pazopanib in metastatic renal carcinoma (mRC): Experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice.
e15609 Background: In clinical trials pazopanib (P) was superior to placebo, noninferior to sunitinib, and very well tolerated as… 
2012
2012
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
BACKGROUND Almost 30% of the sunitinib-treated patients for metastatic renal carcinoma (mRCC) do not receive a clinical benefit… 
2012
2012
Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics.
366 Background: Two randomized trials published in 2001 established cytoreductive nephrectomy (CyNx) for patients (pts) with… 
2012
2012
Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics.
366 Background: Two randomized trials published in 2001 established cytoreductive nephrectomy (CyNx) for patients (pts) with… 
2011
2011
Second-line everolimus treatment is effective in RCC patients with poor progression-free survival (PFS) in first-line VEGF-targeted therapies.
e15028 Background: Everolimus is a standard second line treatment after failure of a VEGF targeted agent in patients (pts.) with… 
1993
1993
Preuminary report of a french multicentric randomised study (CRECY) of immunotherapy in patients with metastatic renal carcinoma (MRC)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)